2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle
06/22/17Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
CARLSBAD, Calif., June 22, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients with Huntington's disease (HD). Dosing in the final patient cohort continues, and Ionis plans to report top-line results from this study around year-end 2017. The safety and tolerability profile of IONIS-HTTRx in the completed cohorts of the Phase 1/2a study suppor... 
06/20/17Akcea Therapeutics Launches Proposed Initial Public Offering
CAMBRIDGE, Mass., June 20, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced that it has launched the proposed initial public offering of its common stock. Akcea is offering 9,620,000 shares of common stock and the underwriters will have a 30-day option to purchase up to an additional 1,443,000 shares of common stock. The initial public offering price is currently expected to be between $12.00 and $14.00 per share.  Akcea has applied to list the s... 
06/01/17SPINRAZA® (nusinersen) Approved in the European Union
First Approved Treatment in EU for SMA Approved to Treat Broad Range of People with SMA Ionis Earns $50 Million Milestone CARLSBAD, Calif., June 1, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the European Commission (EC) has granted marketing authorization for SPINRAZA® (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases. SPINRAZA is th... 
05/25/17Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
CAMBRIDGE, Mass., May 25, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the publication in The New England Journal of Medicine of key preclinical findings with angiopoietin-like 3 (ANGPTL3)-targeting drugs and Phase 1/2 clinical study results with AKCEA-ANGPTL3-LRx (formerly IONIS-ANGPTL3-LRx). In the Phase 1/2 clinical study, treatment with AKCEA-ANGPTL3-LRx resulted in substantial, dose-dependent reductions in ... 
05/15/17Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Webcast to Discuss Results May 15, 2017 at 8:30 am ET CARLSBAD, Calif., May 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the Phase 3 NEURO-TTR study of inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints. Over the 15-month period of the study, inotersen-treated patients achieved statistically significant benefit compared to placebo in the modified Neuropathy Impairment Score +7 (mNIS+... 
05/11/17Ionis Pharmaceuticals Provides Corporate Update at 2017 Annual Meeting of Stockholders
CARLSBAD, Calif., May 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that management will present a general corporate update in conjunction with its 2017 Annual Meeting of Stockholders and Open House on Wednesday, May 24 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA. The agenda for the meeting is as follows: 2:00 p.m. – 2:10 p.m. PT – Annual Meeting of Stockholders (for stockholders of record as o... 
05/10/17Ionis Pharmaceuticals to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
CARLSBAD, Calif., May 10, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 9:20 a.m. Pacific Time on Wednesday, May 17, 2017 in Las Vegas, NV. A live webcast of the presentation will be available on the "Investors & Media" section of the Ionis website at www.ionispharma.com. The replay will be av... 
05/09/17Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors
Mr. Fitzgerald Adds Corporate Finance Expertise to Board CAMBRIDGE, Mass., May 9, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the appointment of Edward Fitzgerald to the company's board of directors.  Mr. Fitzgerald, former executive vice president and chief financial officer of ARIAD Pharmaceuticals, joins Akcea's board of directors as chair of the board's audit committee.  Mr. Fitzgerald's appointment, alo... 
05/09/17Ionis Reports Financial Results and Highlights for First Quarter 2017
Profitable First Quarter with Operating Income of $14 Million and Net Income of $3 Million First Full Quarter of Commercial Revenues from SPINRAZA Conference Call Webcast Tuesday, May 9, 11:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., May 9, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported significantly improved financial results over the same period last year with operating income of $14 million and net income of $3 million, both on a GAAP basis. Th... 
04/26/17Ionis Pharmaceuticals to Hold First Quarter 2017 Financial Results Webcast
Webcast scheduled for Tuesday, May 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif., April 26, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, May 9 at 11:30 a.m. Eastern Time to discuss its first quarter 2017 financial results and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. ... 
04/24/17Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
      Presymptomatic Infants Continued to Achieve Motor Milestones Generally Consistent with Normal Development in New Interim Data Analysis    Positive Data Across a Broad Range of Individuals with SMA Presented at the American Academy of Neurology Annual Meeting    April 24, 2017 07:30 AM Eastern Daylight Time      CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) will present Phase 3 end of study SPINRAZA®(nusinersen) data from CHERISH, ... 
04/21/17Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
First SMA Treatment Recommended for Approval in the EU CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 21, 2017-- Biogen (NASDAQ: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a marketing authorization for SPINRAZA® (nusinersen) to treat patients with spinal muscular atrophy (SMA). The CHMP reviewed SPINRAZA under an accelerated assessment program, which is a regulatory mech... 
04/18/17Ionis Enters into Collaboration with Ribo to Advance RNA-Targeted Therapeutics in China
- Ionis gains a key partner in China to develop up to three Generation 2+ antisense drugs in metabolic disease and cancer - Ribo to commit significant resources to advance Ionis' single-stranded RNAi (ssRNAi) technology - Ionis retains rights to develop and commercialize ssRNAi technology and all drugs under the collaboration outside of China CARLSBAD, Calif., April 18, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced a collaboration and license agreement ... 
03/30/17Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease
CAMBRIDGE, Mass., March 30, 2017 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the initiation of a Phase 2b dose-ranging study of AKCEA-APO(a)-LRx in patients with hyperlipoproteinemia(a) and established cardiovascular disease. The goal of the study is to determine the dose level and frequency for use of AKCEA-APO(a)-LRx in a planned Phase 3 cardiovascular outcome study. AKCEA-APO(a)-LRx is pa... 
03/29/17Ionis Pharmaceuticals to Present at Needham Healthcare Conference
CARLSBAD, Calif., March 29, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 in New York, NY. A live webcast of the presentations will be available on the "Investors & Media" section of the Ionis website at www.ionispharma.com. The replay will be available within 48 hours and will be ar... 
03/28/17Akcea Therapeutics Announces Three Additions to Board of Directors
CAMBRIDGE, Mass., March 28, 2017 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced three additions to the company's board of directors: Christopher Gabrieli, partner emeritus of Bessemer Venture Partners. Mr. Gabrieli will serve as chairman of the board of Akcea Therapeutics. Elaine Hochberg, former chief commercial officer of Forest Laboratories. Sandford D. Smith, founder and chairman of Globa... 
03/27/17Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering
CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not been determined. Akcea has applied to list its common stock on the Nasdaq Global Market under the trading symbol "AKCA." ... 
03/06/17Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
77% Mean Triglyceride Reduction in Patients with FCS Reductions in Pancreatitis Events and Abdominal Pain Webcast to Discuss Results March 6, 2017 at 8:30 am ET CARLSBAD, Calif. and CAMBRIDGE, Mass., March 6, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that the pivotal Phase 3 APPROACH study of volanesorsen met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronem... 
02/28/17Ionis' 2016 Financial Results Outperform Financial Guidance
Conference Call Webcast Tuesday, February 28, 11:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Feb. 28, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.2 million in cash, cash equivalents and short-term investments. The Company also reported a GAAP loss from operations of $46.3 million. "2016 was a year o... 
02/16/17Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
- Ionis and Akcea to receive $75 million up-front payment - Deal valued at more than $1 billion CARLSBAD, Calif. and CAMBRIDGE, Mass., Feb. 16, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced today they have closed on their exclusive, worldwide option and collaboration agreement with Novartis to develop and commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx following clearance unde... 
02/15/17Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call
Webcast scheduled for Tuesday, February 28 at 11:30 a.m. Eastern Time CARLSBAD, Calif., Feb. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, February 28 at 11:30 a.m. Eastern Time to discuss its 2016 financial results and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com.  A ... 
02/14/17Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
CARLSBAD, Calif., Feb. 14, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the advancement of IONIS-FXIRx  in clinical development under an existing exclusive license agreement with Bayer. Under this agreement, Ionis will also initiate development of IONIS-FXI-LRx, which uses Ionis' proprietary LIgand Conjugated Antisense, or LICA, technology.  In conjunction with the decision to advance these programs, Ionis will receive a $75 million payment from Bayer.   ... 
02/02/17Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
CARLSBAD, Calif., Feb. 2, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development.  ... 
02/01/17Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 1, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 in New York, NY; and Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 in Boston, MA. The above listed ... 
01/13/17New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Primary Endpoint from End of Study Analysis Presented at British Paediatric Neurology Association Annual Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA) compared to untreated infants. The data were prese... 
01/06/17Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
Strong financial performance resulting from the continued success of pipeline programs CARLSBAD, Calif., Jan. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the Company expects to significantly improve upon its 2016 financial guidance.  Ionis expects to end 2016 with pro forma net operating income in the low to mid $20 million range and more than $650 million in cash.  The Company's significantly improved financial guidance is the result of numerous ac... 
01/06/17Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
- Collaboration with Novartis provides near-term payments of $225 million plus potential license fees, milestone and royalty payments - Akcea retains rights to co-commercialize to lipid specialists - Deal valued at significantly over $1 billion if both drugs are licensed and successfully commercialized - Company to host conference call at 9:30 a.m. Eastern Time CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals Inc. (NASDAQ: IONS) and Akcea Ther... 
01/04/17Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes
- Company to present top-line results at Pipeline Update Webcast on January 5 - CARLSBAD, Calif., Jan. 4, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes.  In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGRRx achieved robust and sustained, statistically significant improvements in hemoglobin A1c (HbA1c) and ...